Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936676 · ClinicalTrials.gov registry record
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
A clinical trial of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- 684
- Enrollment target
- 20
- Study locations
NCT00936676 is a study of Parkinson's Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 684 participants, roughly in line with the 638-participant average among 156 other Parkinson's Disease trials with a reported enrollment target. The trial reports 20 study locations across 8 states.
The verdict
NCT00936676, a study of Parkinson's Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- 684 participants
- Enrollment target
- 20
- Study locations
Study Summary
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from restarting treatment can also be considered for enrollment in the Core follow-up study period. Use of any other anti-PD treatment is permitted as deemed necessary by the treating physician (according to the participants clinical status).
Conditions Studied
Interventions
- DRUG rasagiline mesylate
Study Locations (20)
California
- Teva Investigational Site 7018 - Irvine
- Teva Investigational Site 7019 - La Jolla
- Teva Investigational Site 7039 - Loma Linda
- Teva Investigational Site 7023 - Los Angeles
- Teva Investigational Site 7022 - Sunnyvale
Florida
- Teva Investigational Site 7020 - Boca Raton
- Teva Investigational Site 7011 - Gainesville
- Teva Investigational Site 7045 - Miami
- Teva Investigational Site 7017 - Tampa
Illinois
- Teva Investigational Site 7013 - Chicago
- Teva Investigational Site 7052 - Chicago
- Teva Investigational Site 7001 - Northbrook
- Teva Investigational Site 7008 - Springfield
Connecticut
- Teva Investigational Site 7024 - Danbury
- Teva Investigational Site 7016 - Farmington
Georgia
- Teva Investigational Site 7055 - Atlanta
- Teva Investigational Site 7043 - Augusta
Alabama
- Teva Investigational Site 7054 - Birmingham
Arizona
- Teva Investigational Site 7006 - Tucson
Iowa
- Teva Investigational Site 7037 - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936676
The ClinicalTrials.gov registry entry for NCT00936676 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 684 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 638-participant average among 156 other Parkinson's Disease trials with a reported enrollment target. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which rasagiline mesylate is the first listed.
NCT00936676 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00936676 about?
NCT00936676 is a clinical study titled "ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects". Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from resta...
What is the current status of trial NCT00936676?
This trial is currently completed. The enrollment target is 684 participants. The study started on 2009-07. Estimated completion is 2013-03.
What conditions does trial NCT00936676 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00936676?
The interventions under investigation include: rasagiline mesylate (DRUG).
Who is sponsoring clinical trial NCT00936676?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00936676 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.